Feature | TCT | November 09, 2017

TCT 2017 Late-breaking Clinical Trial Presentations

TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.

November 9, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has selected 12 late-breaking clinical trials and 16 first report Investigations that are guaranteed to impact patient care and future directions in cardiovascular technologies. 

 

Monday, October 30 - Main Arena I

Late-Breaking Clinical Trials 1

CULPRIT-SHOCK: A Randomized Trial of Multivessel PCI in Cardiogenic Shock. Presenter is Holger Thiele.

EXCEL QOL: Quality of Life After PCI vs. CABG in Left Main Coronary Artery Disease. Presenter is Suzanne J. Baron.

DKCRUSH-V: A Randomized Trial of Double Kissing Crush vs. Provisional Stenting for Treatment of Distal Left Main Bifurcation Lesions. Presenter is Shao-Liang Chen.

 

 

First Report Investigations 1

HREVS: A Randomized Trial of PCI vs. CABG vs Hybrid Revascularization in Patients With Coronary Artery Disease. Presenter is Vladimir Ganyukov.

HARMONEE: A Randomized Trial of a Bioabsorbable Polymer-Based DES With a Luminal CD34+ Antibody Coating vs. a Durable Polymer-Based DES in Patients With Coronary Artery Disease. Presenter is Shigeru Saito.

DARE: A Randomized Trial of a Drug-Eluting Balloon vs. a Metallic DES in Patients With Coronary Artery In-Stent Restenosis. Presenter is Jose P.S. Henriques.

VAMPIRE 3: A Randomized Trial of Distal Filter Protection During PCI of High-Risk Plaque. Presenter is Kiyoshi Hibi. 

 

 

Tuesday, October 31, 2017 - Main Arena II

Late-Breaking Clinical Trials 2: Co-sponsored by the Lancet

ABSORB IV: 30-Day Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs. a Metallic DES in Patients With Coronary Artery Disease. Presented by Gregg W. Stone.

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease. Presented by Stephen G. Ellis.

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis. Presented by David J. Cohen.

 

 

 

First Report Investigations 2

ABSORB II: 4-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease. Presented by Bernard R. Chevalier.

CrossBoss First: A Randomized Trial of Antegrade Dissection and Re-entry vs Standard Wire Escalation for Crossing Coronary Artery Chronic Total Occlusions. Presented by Emmanouil S. Brilakis.

REVASC: A Randomized Trial to Assess Recovery of Left Ventricular Function After PCI of Coronary Artery Chronic Total Occlusions. Presented by Kambis Mashayekhi.

FAVOR II China: Diagnostic Accuracy of the Angiographic Quantitative Flow Ratio (QFR) FFR-Angiography in Patients With Coronary Artery Disease. Presented by Bo Xu.

FAVOR II Europe Japan: Diagnostic Accuracy of the Angiographic Quantitative Flow Ratio (QFR) FFR-Angiography in Patients With Coronary Artery Disease. Presented by Jelmer Westra.

 

 

Wednesday, November 1, 2017 - Main Arena III

Late-Breaking Clinical Trial 3: Co-sponsored by the Journal of the American Medical Association

SENIOR: A Randomized Trial of a Bioabsorbable Polymer-Based Metallic DES vs. a BMS With Short DAPT in Patients With Coronary Artery Disease Older Than 75 Years. Presented by Olivier Varenne.

DAPT STEMI: A Randomized Trial of 6-Month vs. 12-Month DAPT After DES Implantation in STEMI. Presented by Elvin Kedhi.

REDUCE: A Randomized Trial of 3-Month vs 12-Month DAPT After Implantation of a Bioabsorbable Polymer-Based Metallic DES With a Luminal CD34+ Antibody Coating in Patients With ACS. Presented by Harry Suryapranata.

 

 

First Report Investigations 3

MITRAL: 30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Valve Disease Secondary to Mitral Annular Calcification or Failed Annuloplasty Rings. Presented by Mayra Guerrero.

INTREPID: 30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Regurgitation. Presented by Paul Sorajja.

TENDYNE: 1-Year Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Regurgitation. Presented by David W.M. Muller.

TRACER: 6-Month Outcomes of Transcatheter MV Neochordal Repair with the Harpoon System in Patients With Severe Primary Mitral Regurgitation. Presented by James S. Gammie.

MAVERIC: 6-Month Outcomes of Transcatheter MV Repair in Patients With Severe Secondary Mitral Regurgitation. Presented by Stephen G. Worthley.

 

 

Thursday, November 2, 2017 - Main Arena IV

Late-Breaking Clinical Trials 4

PREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure (LAA) vs. Medical Therapy in Patients With Non-Valvular Atrial Fibrillation. Presented by Vivek Y. Reddy.

ORBITA: A Randomized, Sham-Controlled Trial of PCI in Patients With Coronary Artery Disease. Presented by Rasha Al-Lamee.

FAME 2: 3-Year Clinical and Cost-Effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease. Presented by William F. Fearon.

 

 

First Report Investigations 4

TRI-REPAIR: 30-Day Outcomes of Transcatheter TV Repair in Patients With Severe Secondary Tricuspid Regurgitation. Presented by Georg Nickenig.

FORMA: 30-Day Outcomes of Transcatheter TV Repair in Patients With Severe Secondary Tricuspid Regurgitation. Presented by Susheel K. Kodali.

 

 

Other Studies, Videos and Articles From TCT 2017

VIDEO: What Went Wrong With the Absorb Stent? – discussion on the Absorb trials at TCT 2017 with Ajay Kirtane, M.D.

Current State of Bioresorbable Stent Technology

Positive, Sustained Improvements Seen at One Year in SCOUT I With Transcatheter Tricuspid Repair

VIDEO: Transcatheter Mitral Valve Implantation in Practice and Technologies in Development

VIDEO: The Role and Responsibilities of the Cath Lab Manager

VIDEO: New Frontiers in Radial Access

VIDEO: TAVR For Asymptomatic Severe Aortic Stenosis – with Philippe Genereux, M.D.

SURTAVI and FORWARD Studies Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Patients

VIDEO: Overview of the National Cardiogenic Shock Initiative — with William W. O’Neill, M.D.

Supersaturated Oxygen Therapy Reduces Infarct Size for High-Risk Stented AMI Patients

VIDEO: How Transcatheter PFO Closure Can Reduce Cryptogenic Stroke — with John Rhodes, M.D.

VIDEO: Update of Mitral Valve Repair and Replacement Technologies — with Ted Feldman, M.D.

4C Medical's Novel Transcatheter Mitral Valve Presented at TCT 2017 Shark Tank Innovation Competition

VIDEO: Cath Lab of the Future Cardiovascular Technologies to Watch — with Juan Granada, M.D.

VIDEO: Converting to Bundled Payments for PCI — with Peter Duffy, M.D.

 

For more information: www.crf.org/tct/agenda/2017-late-breaking-trials-and-first-report-investigations

 

 

Links to Late-breaking Trials at Other Meetings: 

SCAI 2017 Late-Breaking Clinical Trial Presentations

Heart Rhythm Society 2017 Late-Breaking Electrophysiology Trials

ACC 2017 Late-Breaking Trials

TCT 2016 Late-breaking Trials and First Reports

Related Content

Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
Overlay Init